| A Global Phase III Study of Rilvegostomig or Pembrolizumab Monotherapy for First-Line Treatment | Phase III | rekrutiert |
| A Non-interventional Study for Kisqali (Ribociclib) in Combination With an Aromatase Inhibitor f | — | rekrutiert |
| A Phase II Randomized, Open Label Non-inferiority Study of NiraParib Maintenance After 3 vs. 6 C | Phase II | rekrutiert |
| A Phase III Study of AZD0780 on Major Adverse CV Events in Patients With a History of ASCVD Even | Phase III | rekrutiert |
| A Phase III Study of Dato-DXd With or Without Durvalumab Compared With Investigator's Choice of | Phase III | rekrutiert |
| A Phase III Study to Investigate the Efficacy and Safety of Elecoglipron Compared With Placebo i | Phase III | rekrutiert |
| A Phase Ⅲ Clinical Study of HLX22 in Combination With Trastuzumab and Chemotherapy for the Treat | Phase III | rekrutiert |
| A Study Evaluating the Safety and Efficacy of Targeted Therapies in Subpopulations of Patients W | Phase I | rekrutiert |
| A Study of Rilvegostomig or Durvalumab Plus Chemotherapy for First-Line Treatment of Biliary Tra | Phase III | rekrutiert |
| A Study to Evaluate the Efficacy and Safety of Ifinatamab Deruxtecan (I-DXd) in Subjects With Re | Phase I / Phase II | rekrutiert |
| BioPearl™ Microspheres Loaded With Doxorubicin for the Treatment of Unresectable Hepatocellular | ohne Phasenangabe | rekrutiert |
| Bleximenib in Combination With Standard Induction and Consolidation Therapy Followed by Maintena | Phase III | rekrutiert |
| Capivasertib + CDK4/6i + Fulvestrant for Advanced/Metastatic HR+/HER2- Breast Cancer (CAPItello- | Phase III | rekrutiert |
| Comprehensive Analysis of Spatial, Temporal and Molecular Patterns of Ribociclib Efficacy and Re | Phase IV | rekrutiert |
| EASi-KIDNEY™ (The Studies of Heart & Kidney Protection With BI 690517 in Combination With Empagl | Phase III | rekrutiert |
| Early Catheter-directed Treatment of High Risk Pulmonary Embolism | ohne Phasenangabe | rekrutiert |
| FS222 First in Human Study in Patients With Advanced Malignancies | Phase I | rekrutiert |
| GMALL Registry and Collection of Biomaterial: Prospective Data Collection Regarding Diagnosis, T | — | rekrutiert |
| GMMG Multiple Myeloma Registry | — | rekrutiert |
| German Cardiac Arrest Registry | — | rekrutiert |
| German MPN-Registry for BCR-ABL 1-Negative Myeloid Neoplasms (Study Group Ulm) | — | rekrutiert |
| Iberdomide vs. Iberdomide Plus Isatuximab Maintenance Therapy Post ASCT in Newly Diagnosed Multi | Phase III | rekrutiert |
| International HIT-MED Registry (I-HIT-MED) | — | rekrutiert |
| Intrathecal Application of PD1 Antibody in Metastatic Solid Tumors With Leptomeningeal Disease ( | Phase I | rekrutiert |
| Ivosidenib and Azacitidine With or Without Venetoclax in Adult Patients With Newly Diagnosed IDH | Phase III | rekrutiert |
| NIS to Examine the Effectiveness and Safety of Durvalumab and Olaparib in Patients With Endometr | — | rekrutiert |
| NeoAdj. Therapy Comparing Sacituzumab Govitecan (SG) vs. SG+Pembrolizumab in Low-risk, Triple-ne | Phase III | rekrutiert |
| Niraparib vs Niraparib Plus Bevacizumab in Patients With Platinum/Taxane-based Chemotherapy in A | Phase III | rekrutiert |
| ORACLE: Observation of ResiduAl Cancer With Liquid Biopsy Evaluation | — | rekrutiert |
| PROVIDENCE - Prospective Non-interventional Study (NIS) to Examine Patient-reported Outcomes and | — | rekrutiert |
| Pan Tumor Rollover Study | Phase II | rekrutiert |
| Phase 2 Trial of Adagrasib Monotherapy and in Combination With Pembrolizumab and a Phase 3 Trial | Phase II / Phase III | rekrutiert |
| Phase III Study of Induction and Consolidation Chemotherapy With Venetoclax in Patients With New | Phase III | rekrutiert |
| Puxitatug Samrotecan (AZD8205) Monotherapy vs Chemotherapy in B7-H4-selected Endometrial Cancer | Phase III | rekrutiert |
| Register Schweres Asthma - German Asthma Net e.V. | — | rekrutiert |
| Registry Study on Patient Characteristics, Biological Disease Profile and Clinical Outcome in Ac | — | rekrutiert |
| Retrospective Prospective Multicentric Clinical Follow up of Patients After Being Treated With T | — | rekrutiert |
| Revumenib in Combination With Azacitidine + Venetoclax in Patients NPM1-mutated or KMT2A-rearran | Phase III | rekrutiert |
| Sonesitatug Vedotin in Combination With Capecitabine With or Without Rilvegostomig in Participan | Phase III | rekrutiert |
| Study to Evaluate Adverse Events and Efficacy of Intravenous (IV) Telisotuzumab Adizutecan in Co | Phase I / Phase II | rekrutiert |
| Treatment Protocol for Children and Adolescents With Acute Lymphoblastic Leukemia - AIEOP-BFM AL | Phase III | rekrutiert |